Hydrochlorothiazid Léčiva (Hydrochlorothiazide)

Hydrochlorothiazid Léčiva is prescribed when clinicians need to lower elevated arterial pressure or remove excess extracellular fluid, making it useful in a range of cardiovascular and hepatic or renal conditions.

• Hypertension (essential or secondary) requiring diuretic therapy.
• Edema associated with congestive heart failure.
• Ascites or peripheral edema secondary to hepatic cirrhosis.
• Fluid retention in chronic kidney disease or nephrotic syndrome.
• Adjunctive treatment with other antihypertensive agents to achieve target blood pressure.

• Hydrochlorothiazide acts by inhibiting the sodium‑chloride symporter located in the distal convoluted tubule of the nephron. Blocking this Na⁺/Cl⁻ cotransporter reduces reabsorption of sodium and chloride, which creates an osmotic gradient that retains water in the tubular lumen, increasing urinary excretion of sodium, chloride, and water. The resulting decrease in extracellular fluid volume contributes to significantly lower systemic blood pressure.

Hydrochlorothiazid Léčiva may cause a range of adverse reactions, most of which are mild and reversible, while a few can be serious and require medical attention.

Common

• Increased urination (polyuria).
• Low potassium levels (hypokalemia).
• Low sodium levels (hyponatremia).
• Elevated blood glucose (hyperglycemia).
• Dizziness or light‑headedness, especially on standing (orthostatic hypotension).
• Elevated uric acid leading to gout attacks.

Serious

• Severe electrolyte disturbances (e.g., hyponatremia, hypokalemia).
• Acute kidney injury or worsening renal function.
• Allergic reactions such as rash, Stevens‑Johnson syndrome, or anaphylaxis.
• Severe dehydration leading to hypotension.
• Blood disorders such as leukopenia or thrombocytopenia.

Before initiating therapy with Hydrochlorothiazid Léčiva, clinicians should evaluate several patient‑specific factors to minimize risk and ensure appropriate use.

• Assess renal function; avoid use in severe impairment.
• Monitor electrolytes, especially potassium and sodium, during treatment.
• Use cautiously in patients with diabetes or gout.
• Evaluate for sulfonamide allergy, as hydrochlorothiazide is a sulfonamide derivative.
• Consider pregnancy status; safety data are limited.
• Review concomitant use of other diuretics or antihypertensives to prevent excessive volume depletion.
• Advise patients to rise slowly from sitting or lying to reduce orthostatic dizziness.

Hydrochlorothiazid Léčiva can alter the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with lithium, which may increase lithium toxicity.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can blunt diuretic efficacy and impair renal function.
• Co‑administration with ACE inhibitors or ARBs in patients at risk for severe potassium loss.

Use with caution

• Antidiabetic agents, as diuretic‑induced hypokalemia may enhance hypoglycemia.
• Cardiac glycosides (e.g., digoxin) due to increased risk of arrhythmia from electrolyte shifts.
• Corticosteroids, which may potentiate fluid loss.
• Anticoagulants, where volume depletion can affect drug levels.